medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2023, Número 1

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2023; 34 (1)


Vacunación contra la influenza para la prevención primaria y secundaria del riesgo cardiovascular: una llamada para la acción de las Sociedades Cardiológicas de México

Guerra A, Cossío J, Enciso JM, Alcocer A, Gómez-Álvarez E, Meaney E, Palomo S, Alcocer L

Idioma: Inglés [English version]
Referencias bibliográficas: 39
Paginas: 26-27
Archivo PDF: 196.82 Kb.


RESUMEN

La influenza aumenta sustancialmente el riesgo de desencadenar síndromes coronarios agudos e insuficiencia cardiaca. La vacunación contra la influenza disminuye estos riesgos y disminuye la aparición de complicaciones. Se recomienda la vacunación de toda la población, especialmente las personas con riesgo o con enfermedad cardiovascular establecida.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Organización Panamericana de la Salud. Influenza y otros virus respiratorios. Washington, D.C.: OPS. Disponible en: https://www.paho.org/es/temas/influenza-otros-virus-respiratorios

  2. Corral M, Castro STEW, To TM, Arndorfer S, Wang S, Stephens J. Burden of influenza in patients with cardiovascular disease who receive antiviral treatment for influenza. J Med Econ. 2022; 25: 1061-1067. doi: 10.1080/13696998.2022.2111910.

  3. Chow EJ, Rolfes MA, O'Halloran A, Anderson EJ, Bennett NM, Billing L et al. Acute cardiovascular events associated with influenza in hospitalized adults: a cross-sectional study. Ann Intern Med. 2020; 173: 605-613. doi: 10.7326/M20-1509.

  4. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015; (5): CD005050. doi: 10.1002/14651858.CD005050.pub3.

  5. LeBras MH, Barry AR. Influenza vaccination for secondary prevention of cardiovascular events: a systematic review. Can J Hosp Pharm. 2017; 70: 27-34. doi: 10.4212/cjhp.v70i1.1626.

  6. Rodrigues BS, David C, Costa J, Ferreira JJ, Pinto FJ, Caldeira D. Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies. Heart. 2020; 106: 350-357. doi: 10.1136/heartjnl-2019-315193.

  7. Behrouzi B, Bhatt DL, Cannon CP, Vardeny O, Lee DS, Solomon SD, Udell Ha. Association of influenza vaccination with cardiovascular risk: a meta-analysis. JAMA Netw Open. 2022; 5: E228873. doi: 10.1001/jamanetworkopen.2022.8873.

  8. Frobert O, Gotberg M, Erlinge D, Akhtar Z, Christiansen EH, Macintyre CR et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation. 2021; 144: 1476-1484. doi: 10.1161/CIRCULATIONAHA.121.057042.

  9. Liprandi AS, Liprandi MIS, Zaidel EJ, Aisenberg GM, Baranchuk A, Barbosa ECD et al. Influenza vaccination for the prevention of cardiovascular disease in the Americas: consensus document of the Inter-American Society of Cardiology and the Word Heart Federation. Glob Heart. 2021; 16: 55. doi: 10.5334/gh.1069.

  10. Influenza (Seasonal). Available in: http://www.who.int/mediacentre/factsheets/fs211/en/

  11. Chow EJ, Rolfes MA, O'Halloran A, Anderson EJ, Bennett NM, Billing L et al. Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults: A Cross-sectional Study. Ann Intern Med. 2020; 173 (8): 605-613. doi: 10.7326/M20-1509.

  12. Madjid M, Miller CC, Zarubaev VV et al. Influenza epidemics, and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects. Eur Heart J. 2007; 28 (10): 1205-1210. doi: 10.1093/eurheartj/ehm035.

  13. Kwong JC, Schwartz KL, Campitelli MA et al. Acute myocardial infarction after laboratory confirmed influenza infection. N Engl J Med. 2018; 378 (4): 345-353. doi: 10.1056/NEJMoa1702090.

  14. Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018; 51 (3): 1701794. doi: 10.1183/13993003.01794-2017.

  15. Chang TY, Chao TF, Liu CJ et al. The association between influenza infection, vaccination, and atrial fibrillation: a nationwide case-control study. Heart Rhythm. 2016; 13 (6): 1189-1194. doi: 10.1016/j.hrthm.2016.01.026.

  16. Kytomaa S, Hegde S, Claggett B et al. Association of influenza-like illness activity with hospitalizations for heart failure: the atherosclerosis risk in communities study. JAMA Cardiol. 2019; 4 (4): 363-369. doi: 10.1001/jamacardio.2019.0549.

  17. Panhwar MS, Kalra A, Gupta T et al. Effect of influenza on outcomes in patients with heart failure. JACC Heart Fail. 2019; 7 (2): 112-117. doi: 10.1016/j.jchf.2018.10.011.

  18. LeBras MH, Barry AR. Influenza vaccination for secondary prevention of cardiovascular events: a systematic review. Can J Hosp Pharm. 2017; 70 (1): 27-34. doi: 10.4212/cjhp.v70i1.1626.

  19. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002; 105 (18): 2143-2147. doi: 10.1161/01.cir.0000016182.85461.f4.

  20. Ciszewski A, Bilinska ZT, Brydak LB et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008; 29 (11): 1350-1358. doi: 10.1093/eurheartj/ehm581.

  21. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with the acute coronary syndrome. EurHeart J. 2011; 32 (14): 1730-1735. doi: 10.1093/eurheartj/ehr004.

  22. Keshtkar-Jahromi M, Vakili H, Rahnavardi M et al. The efficacy of influenza vaccination in reducing cardiovascular events in patients with coronary artery diseases: IVCAD study [abstract]. Clin Microbiol Infect. 2009; 15 (S4): S395-396.

  23. Udell JA, Zawi R, Bhatt DL et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013; 310 (16): 1711-1720. doi: 10.1001/jama.2013.279206.

  24. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015; (5): CD005050. doi: 10.1002/14651858.CD005050.pub3.

  25. Yedlapati SH, Khan SU, Talluri S et al. Effects of influenza. vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021; 10: E019636. doi: 10.1161/JAHA.120.019636.

  26. Wu W-C, Jiang L, Friedmann PD, Trivedi A. Association between process quality measures for heart failure and mortality among U.S. veterans. Am Heart J. 2014; 168 (5): 713-720. doi: 10.1016/j.ahj.2014.06.024.

  27. Mohseni H, Kiran A, Khorshidi R, Rahimi K. Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study. Eur Heart J. 2017; 38 (5): 326-333. doi: 10.1093/eurheartj/ehw411.

  28. Modin D, Jorgensen ME, Gislason G et al. Influenza vaccine in heart failure. Circulation. 2019; 139 (5): 575-586. doi: 10.1161/CIRCULATIONAHA.118.036788.

  29. Rodrigues BS, David C, Costa J, Ferreira JJ, Pinto FJ, Caldeira D. Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies. Heart Br Card Soc. 2020;106 (5): 350-357. doi: 10.1136/heart jnl-2019-315193.

  30. Vardeny O, Kim K, Udell JA et al. Effect of high-dose trivalent vs. standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial. JAMA. 2021; 325 (1): 39-49. doi: 10.1001/jama.2020.23649.

  31. Loeb M, Dokainish H, Dans A et al. Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design. Am Heart J. 2019; 212: 36-44. doi: 10.1016/j.ahj.2019.02.009.

  32. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med. 2015; 13 (1): 53. doi: 10.1186/s12916- 015-0295-6.

  33. Modin D, Claggett B, Jorgensen ME, Kober L, Benfield T, Schou M et al. Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study. J Am Heart Assoc. 2022; 11 (6): e021715. doi: 10.1161/JAHA.121.021715.

  34. Kao PF, Liu JC, Hsu YP et al. Influenza vaccination might reduce the risk of ischemic stroke in patients with atrial fibrillation: a population-based cohort study. Oncotarget. 2017; 8 (68): 112697-112711. doi: 10.18632/oncotarget.22352.

  35. Grohskopf LA, Alyanak E, Ferdinands JM et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021-2022 influenza season. MMWR Recomm Rep. 2021; 70 (No. RR-5): 1-28. doi: http://dx.doi.org/10.15585/mmwr.rr7005a1.

  36. Diaz Granados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014; 371 (7): 635-45. doi: 10.1056/NEJMoa1315727.

  37. Dunkle LM, Izikson R, Patriarch P et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017; 376: 2427-2436. Available in: https://doi. org/10.1056/NEJMoa1608862

  38. Van Buynder PG, Konrad S, Van Buynder JL et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine. 2013; 31: 6122-6128. Available in: https://doi.org/10.1016/j.vaccine.2013.07.059

  39. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009; 200 (2): 172-180.




2020     |     www.medigraphic.com